# Dr. Agarwal's Health Care (NSE: AGARWALEYE) share price, financials and shareholding Source: https://app.pivotnow.in/stock/AGARWALEYE · Pivot · prices to 22 Oct 2026 Dr. Agarwal's Health Care (NSE: AGARWALEYE) closed at ₹459.10 on 22 Oct 2026, down 1.51% on the day. With a market capitalisation of ₹14,852 Cr, it ranks 426th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector. At its last close the stock traded at 100× trailing earnings, against a return on equity of 6.6% in FY26. Over the past year the share price has fallen 10.7%. Its 52-week range is ₹401.00 (30 Mar 2026) to ₹567.75 (11 Aug 2026); the last close is 19.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹614 Cr (+26.0% year on year) and net profit ₹55 Cr (+44.6%), on a consolidated basis. Promoters held 32.34% of the company as of 30 Jun 2026. ## Key numbers | Metric | Value | | --- | --- | | Last close | ₹459.10 | | Market cap | ₹14,852 Cr | | P/E (trailing) | 100 | | ROE | 6.6% (FY26) | | ROCE | 9.7% (FY26) | | Debt to equity | 0.08 | | 52-week high | ₹567.75 (11 Aug 2026) | | 52-week low | ₹401.00 (30 Mar 2026) | | 1-year return | −10.7% | ## Quarterly results (₹ crore, consolidated) | Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) | | --- | --- | --- | --- | --- | --- | | Q1 FY27 | ₹614 Cr | +26.0% | ₹55 Cr | +44.6% | ₹1.43 | | Q4 FY26 | ₹564 Cr | +22.6% | ₹50 Cr | +17.4% | ₹1.25 | | Q3 FY26 | ₹530 Cr | +23.0% | ₹44 Cr | +54.5% | ₹1.07 | | Q2 FY26 | ₹499 Cr | +19.7% | ₹36 Cr | +71.0% | ₹0.94 | | Q1 FY26 | ₹487 Cr | +20.8% | ₹38 Cr | +108.9% | ₹0.95 | | Q4 FY25 | ₹460 Cr | +33.6% | ₹43 Cr | +3.0% | ₹1.04 | | Q3 FY25 | ₹431 Cr | +29.5% | ₹28 Cr | +25.0% | ₹0.73 | | Q2 FY25 | ₹417 Cr | — | ₹21 Cr | — | ₹0.57 | ## Annual results (₹ crore) | Fiscal year | Revenue | Net profit | | --- | --- | --- | | FY26 | ₹2,080 Cr | ₹168 Cr | | FY25 | ₹1,711 Cr | ₹110 Cr | | FY24 | ₹1,332 Cr | ₹95 Cr | | FY23 | ₹1,018 Cr | ₹103 Cr | | FY22 | ₹696 Cr | ₹43 Cr | ## Shareholding (30 Jun 2026) - Promoters: 32.34% - Foreign institutions: 57.96% - Domestic institutions: 7.72% - Non-institutions: 1.98% ## Peers | Company | Price | Market cap | P/E | ROE | | --- | --- | --- | --- | --- | | [Eris Lifesciences](https://app.pivotnow.in/stock/ERIS) | ₹1,143.60 | ₹15,537 Cr | 25.3 | 15.9% | | [Alembic Pharmaceuticals](https://app.pivotnow.in/stock/APLLTD) | ₹785.00 | ₹15,357 Cr | 22.9 | 11.2% | | [AstraZeneca Pharma India](https://app.pivotnow.in/stock/ASTRAZEN) | ₹6,056.00 | ₹15,252 Cr | 80.9 | 15.0% | | [Syngene International](https://app.pivotnow.in/stock/SYNGENE) | ₹370.75 | ₹15,037 Cr | 47 | 6.5% | | [Jubilant Pharmova](https://app.pivotnow.in/stock/JUBLPHARMA) | ₹930.80 | ₹14,848 Cr | 37.1 | 13.4% | | [Poly Medicure](https://app.pivotnow.in/stock/POLYMED) | ₹1,479.10 | ₹14,686 Cr | 46.7 | 10.4% | ## Questions and answers ### What is the share price of Dr. Agarwal's Health Care today? Dr. Agarwal's Health Care (NSE: AGARWALEYE) last closed at ₹459.10 on 22 Oct 2026. Its 52-week high is ₹567.75 and its 52-week low is ₹401.00. ### What is the market cap of Dr. Agarwal's Health Care? Dr. Agarwal's Health Care's market capitalisation is ₹14,852 Cr (₹14,852 Cr) at the 22 Oct 2026 close, ranking 426th among the NSE companies Pivot tracks. ### What is the P/E ratio of Dr. Agarwal's Health Care? Dr. Agarwal's Health Care trades at a trailing P/E of 100. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7. ### What is the ROE and ROCE of Dr. Agarwal's Health Care? Return on equity was 6.6% in FY26 and return on capital employed was 9.7% in FY26 (consolidated figures). ### Is Dr. Agarwal's Health Care a debt-free company? No. Dr. Agarwal's Health Care's debt-to-equity ratio was 0.08 in FY26, with total debt of ₹133 Cr. ### What were Dr. Agarwal's Health Care's latest quarterly results? For Q1 FY27 (quarter ended 30 Jun 2026), Dr. Agarwal's Health Care reported revenue of ₹614 Cr, +26.0% year on year, and net profit of ₹55 Cr, +44.6% year on year. ### How has Dr. Agarwal's Health Care stock performed over the last year? Dr. Agarwal's Health Care's share price has fallen 10.7% over the past year, −3.1% over three months and −6.2% over one month, to the 22 Oct 2026 close. ### What is the shareholding pattern of Dr. Agarwal's Health Care? As of 30 Jun 2026: promoters 32.34%, foreign institutions 57.96%, domestic institutions 7.72%, non-institutions 1.98%. ### Who are Dr. Agarwal's Health Care's competitors? The listed Pharma & Healthcare companies closest to Dr. Agarwal's Health Care by market cap are Eris Lifesciences, Alembic Pharmaceuticals, AstraZeneca Pharma India, Syngene International, Jubilant Pharmova and Poly Medicure. ### Is Dr. Agarwal's Health Care a good stock to buy? Pivot does not give buy or sell recommendations. This page sets out Dr. Agarwal's Health Care's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AGARWALEYE against its own history before risking money. This is analysis, not financial advice. --- Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.